Vivesto AB (STO:VIVE)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.2490
+0.0015 (0.61%)
Aug 8, 2025, 4:32 PM CET
0.61%
Market Cap133.97M
Revenue (ttm)n/a
Net Income (ttm)-39.62M
Shares Out538.04M
EPS (ttm)-0.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume223,093
Average Volume420,109
Open0.2475
Previous Close0.2475
Day's Range0.2405 - 0.2535
52-Week Range0.1992 - 0.3655
Beta1.05
RSI63.80
Earnings DateAug 12, 2025

About Summit Materials

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encaps... [Read more]

Sector Healthcare
Founded 1988
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIVE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.